Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer

用于胰腺癌光学手术导航的分子成像探针

基本信息

  • 批准号:
    10557180
  • 负责人:
  • 金额:
    $ 44.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-01 至 2027-01-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Pancreatic cancer (PC) is an aggressive malignancy where surgical resection is the most effective curative option. Reliance on bright light visualization and tactile cues limit the efficiency of surgical resection for PC and its premalignant precursor lesions and contribute to unfavorable outcomes. Intraoperative fluorescence guidance improves both stagings as well as the accuracy of oncologic surgeries and results in lower local recurrence rates and improved survival. The success of fluorescence-guided imaging is dependent on the sensitivity and specificity of a marker being utilized for detecting PC and its precursor lesions. Multiple studies from our laboratory and others have established the differential expression of MUC4 in pancreatic pathologies. While it is undetectable in the normal pancreas, de novo overexpression of MUC4 is restricted to high-risk-precursor lesions and invasive PC and its expression increases progressively disease advancement. An in-house generated monoclonal antibody (mAb) against MUC4, 8G7, which recognizes repetitive epitopes in the tandem repeat domain, has emerged as a useful tool for ultrasensitive detection and defining the role of MUC4 in tumor progression and metastasis. High MUC4 expression in PC is associated with poor survival, while in precursor lesions, MUC4 expression is a predictor of malignant risk. Our preliminary studies indicate that systemically administered mAb 8G7 labeled with NIRF dye IRDye800CW can very sensitively illuminate MUC4-expressing subcutaneous and orthotopic tumors in vivo. Further, we have developed a unique animal model that recapitulates MUC4-driven IPMN-to-invasive PC progression. In this model, pancreas-specific inducible expression of human MUC4 in conjunction with oncogenic KrasG12D results in the development of premalignant IPMN and PanIN lesions that progress to invasive PC. The proposal seeks to develop and evaluate MUC4- targeted NIR probes for optical surgical navigation of PC and its premalignant precursor lesions in the preclinical models. We hypothesize that intraoperative use of MUC4-targeted Near-Infrared Fluorescent (NIRF) imaging probes will improve the resection of PC and its high-risk precursor lesions. To test this hypothesis, two specific aims are proposed. Studies in Aim 1 focus on the synthesis, characterization, and (pre) clinical safety profiling of MUC4-targeted near-infrared fluorescent conjugates. Aim 2 studies evaluate the preclinical efficacy of MUC4-targeted imaging probes in patient-derived orthotopic xenograft (PDOX) models, human MUC4 transgenic GEM models, and clinical specimens. Overall, the development of targeted imaging probes can improve both the detection and margin-free resection of precursor lesions and PC. The studies proposed in this application will develop and test high-performance NIR probes targeting MUC4 (a top differentially overexpressed membrane mucin in PC) for surgical navigation in PC and its precursor lesions. Successful accomplishment of study goals will pave the path for a Phase I clinical trial for urgently needed imaging probes for improved detection and surgical resection of PC and its high-risk precursor lesions.
摘要 胰腺癌是一种侵袭性的恶性肿瘤,手术切除是最有效的治疗方法 选项.对明亮的光可视化和触觉提示的依赖限制了PC的手术切除效率, 它的癌前病变,并有助于不利的结果。术中荧光引导 提高了肿瘤手术的分期和准确性,并降低了局部复发率 提高生存率。荧光引导成像的成功取决于灵敏度和 用于检测PC及其前驱病变的标记物的特异性。我们的多项研究 实验室和其他人已经确定了MUC 4在胰腺病理中的差异表达。虽然 在正常胰腺中检测不到,MUC 4的从头过表达仅限于高风险前体细胞, 病变和侵袭性PC,其表达逐渐增加疾病进展。一个内部 产生了针对MUC 4,8 G7的单克隆抗体(mAb),其识别串联中的重复表位 重复结构域,已成为一个有用的工具,超灵敏检测和确定MUC 4在肿瘤中的作用 进展和转移。PC中MUC 4的高表达与生存率低相关,而在前体细胞中MUC 4的高表达与生存率低相关。 MUC 4表达是恶性风险的预测因子。我们的初步研究表明, 施用的用NIRF染料IRDye 800 CW标记的mAb 8 G7可以非常灵敏地照射MUC 4表达细胞。 皮下和原位肿瘤。此外,我们还开发了一种独特的动物模型, 概括了MUC 4驱动的IPMN至侵袭性PC的进展。在该模型中,胰腺特异性诱导 人MUC 4与致癌KrasG 12 D的表达导致癌前病变的发展 进展为侵袭性PC的IPMN和PanIN病变。该提案旨在开发和评估MUC 4- 用于PC及其癌前病变临床前光学手术导航的靶向NIR探针 模型我们假设术中使用MUC 4靶向近红外荧光(NIRF) 成像探针将改善PC及其高危前驱病变的切除。为了验证这一 假设,提出了两个具体目标。目标1的研究集中在合成,表征和(预) MUC 4靶向近红外荧光缀合物的临床安全性分析。目的2研究评估 MUC 4靶向成像探针在患者来源的原位异种移植(PDOX)模型中的临床前功效, 人MUC 4转基因GEM模型和临床标本。总体而言,靶向成像的发展 探针可以改善前驱病变和PC的检测和无边缘切除。研究 在这项申请中提出的将开发和测试高性能的近红外探针靶向MUC 4(一个顶部 PC中差异过表达的膜粘蛋白)用于PC及其前驱病变中的手术导航。 研究目标的成功实现将为急需的I期临床试验铺平道路。 成像探头用于改善PC及其高危前驱病变的检测和手术切除。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Surinder K. Batra其他文献

Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications
  • DOI:
    10.1007/s10555-007-9052-4
  • 发表时间:
    2007-02-02
  • 期刊:
  • 影响因子:
    8.700
  • 作者:
    Murielle Mimeault;Surinder K. Batra
  • 通讯作者:
    Surinder K. Batra
Wolfram 症候群の実態調査
关于 Wolfram 综合征的事实调查
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yukihiro Tamura;Michiyo Higashi;Sho Kitamoto;Seiya Yokoyama;Masahiko Osako;Michiko Horinouchi;Takeshi Shimizu;Mineo Tabata;Surinder K. Batra;Masamichi Goto;Suguru Yonezawa;松永仁恵,田部勝也,太田康晴,奥屋 茂,和田安彦,山田祐一郎,雨宮 伸,杉原茂孝,岡 芳知,谷澤幸生
  • 通讯作者:
    松永仁恵,田部勝也,太田康晴,奥屋 茂,和田安彦,山田祐一郎,雨宮 伸,杉原茂孝,岡 芳知,谷澤幸生
PP01.05 Targeting MUC16-Mediated KRASi Resistance in NSCLC
PP01.05 针对非小细胞肺癌中 MUC16 介导的 KRASi 耐药性
  • DOI:
    10.1016/j.jtho.2025.03.013
  • 发表时间:
    2025-04-01
  • 期刊:
  • 影响因子:
    20.800
  • 作者:
    Ashu Shah;Shamema Salam;Sanjib Chaudhary;Iniyan A. Muthamil;Imayavaramban Lakshmanan;Surinder K. Batra;Apar K. Ganti
  • 通讯作者:
    Apar K. Ganti
Mo1138 COMPARATIVE PROTEOMICS REVEALS TRANSLATIONAL POTENTIAL OF TARGETS FOR PANCREATIC DUCTAL ADENOCARCINOMA
  • DOI:
    10.1016/s0016-5085(23)02780-4
  • 发表时间:
    2023-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mathilde Resell;Hanne-Line Rabben;Manoj Amrutkar;Lars Hagen;Surinder K. Batra;Caroline S. Verbeke;Timothy C. Wang;Duan Chen;Chun-Mei Zhao
  • 通讯作者:
    Chun-Mei Zhao
MUC5AC in stromal heterogeneity and the Progression of Pancreatic Cancer
  • DOI:
    10.1016/j.canlet.2023.216541
  • 发表时间:
    2024-01-28
  • 期刊:
  • 影响因子:
  • 作者:
    Surinder K. Batra
  • 通讯作者:
    Surinder K. Batra

Surinder K. Batra的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Surinder K. Batra', 18)}}的其他基金

Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer
截短的O-聚糖依赖性机制诱导胰腺癌转移扩散
  • 批准号:
    10683305
  • 财政年份:
    2022
  • 资助金额:
    $ 44.1万
  • 项目类别:
Novel Therapy to Inhibit IPMN Progression
抑制 IPMN 进展的新疗法
  • 批准号:
    10446455
  • 财政年份:
    2022
  • 资助金额:
    $ 44.1万
  • 项目类别:
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer
用于胰腺癌光学手术导航的分子成像探针
  • 批准号:
    10367553
  • 财政年份:
    2022
  • 资助金额:
    $ 44.1万
  • 项目类别:
Novel Therapy to Inhibit IPMN Progression
抑制 IPMN 进展的新疗法
  • 批准号:
    10640955
  • 财政年份:
    2022
  • 资助金额:
    $ 44.1万
  • 项目类别:
Connectivity mapping identified novel combination therapy for glioblastoma
连接映射确定了胶质母细胞瘤的新型联合疗法
  • 批准号:
    10504826
  • 财政年份:
    2022
  • 资助金额:
    $ 44.1万
  • 项目类别:
Connectivity mapping identified novel combination therapy for glioblastoma
连接映射确定了胶质母细胞瘤的新型联合疗法
  • 批准号:
    10686268
  • 财政年份:
    2022
  • 资助金额:
    $ 44.1万
  • 项目类别:
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer
截短的O-聚糖依赖性机制诱导胰腺癌转移扩散
  • 批准号:
    10503433
  • 财政年份:
    2022
  • 资助金额:
    $ 44.1万
  • 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
  • 批准号:
    10156494
  • 财政年份:
    2021
  • 资助金额:
    $ 44.1万
  • 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
  • 批准号:
    10339431
  • 财政年份:
    2021
  • 资助金额:
    $ 44.1万
  • 项目类别:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
用于胰腺癌早期诊断和风险评估的尿液和血清生物标志物
  • 批准号:
    10551280
  • 财政年份:
    2021
  • 资助金额:
    $ 44.1万
  • 项目类别:

相似海外基金

Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
  • 批准号:
    2348998
  • 财政年份:
    2025
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
  • 批准号:
    2348999
  • 财政年份:
    2025
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
Understanding Latin American Challenges in the 21st Century (LAC-EU)
了解拉丁美洲在 21 世纪面临的挑战 (LAC-EU)
  • 批准号:
    EP/Y034694/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Research Grant
Conference: North American High Order Methods Con (NAHOMCon)
会议:北美高阶方法大会 (NAHOMCon)
  • 批准号:
    2333724
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
  • 批准号:
    2346565
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
REU Site: Research Experiences for American Leadership of Industry with Zero Emissions by 2050 (REALIZE-2050)
REU 网站:2050 年美国零排放工业领先地位的研究经验 (REALIZE-2050)
  • 批准号:
    2349580
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
  • 批准号:
    2346564
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
Conference: Latin American School of Algebraic Geometry
会议:拉丁美洲代数几何学院
  • 批准号:
    2401164
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
Collaborative Research: Ionospheric Density Response to American Solar Eclipses Using Coordinated Radio Observations with Modeling Support
合作研究:利用协调射电观测和建模支持对美国日食的电离层密度响应
  • 批准号:
    2412294
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
Conference: Doctoral Consortium at Student Research Workshop at the Annual Conference of the North American Chapter of the Association for Computational Linguistics (NAACL)
会议:计算语言学协会 (NAACL) 北美分会年会学生研究研讨会上的博士联盟
  • 批准号:
    2415059
  • 财政年份:
    2024
  • 资助金额:
    $ 44.1万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了